A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)

OBJECTIVE: Vortioxetine is a monoaminergic drug with a novel multimodal mechanism of action. We investigated its efficacy on depressive symptoms, cognitive function, and quality of life among cancer patients. METHODS: In this multicenter, open-label, single-arm, observational study, patients receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Chong Guan, Abousheishaa, Aya Ahmed, Low, Sue Yin, Zainal, Nor Zuraida, Thong, Kai Shin, Awaluddin, Azizul Bin, Loo, Tsui Huei, Yacob, Sapini Binti, Nik Jaafar, Nik Ruzyanei, Abdul Taib, Nur Iwana Binti, Mohamad Kamal, Nurul Ain Binti, Ismail, Fuad, Wi, Wan Zamaniah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685216/
https://www.ncbi.nlm.nih.gov/pubmed/37642043
http://dx.doi.org/10.31557/APJCP.2023.24.8.2583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685216/
https://www.ncbi.nlm.nih.gov/pubmed/37642043
http://dx.doi.org/10.31557/APJCP.2023.24.8.2583

Ejemplares similares